



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GRUENBERG
Serial No.: 09/127,138
Filed: July 31, 1998
For: AUTOLOGOUS IMMUNE CELL
THERAPY: CELL
COMPOSITIONS, METHODS
AND APPLICATIONS TO
TREATMENT OF HUMAN
DISEASE

Art Unit: 1643
Examiner: Unassigned

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an Information Disclosure Statement and Forms PTO-1449 (14 pages) for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a first office action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account Number 08-1641, as stated below:

(X) The Commissioner is hereby authorized to charge the fee for the Information Disclosure Statement and any other fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 08-1641. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE


By: 
Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24731-500E
Address all correspondence to:
HELLER, EHRMAN, WHITE & McAULIFFE
4250 Executive Square,
La Jolla, California 92037
Telephone: (619) 450-8400
EMAIL sseidman@hewm.com

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Assistant Commissioner for Patents
Washington, D.C. 20231, on this date.

10/22/98
Date


Kathy Holloway

RECEIVED
OCT 28 PM 3:02
GROUP 180

#5/100/78413
Goddard 11/05/98



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GRUENBERG

Serial No.: 09/127,138

Filed: July 31, 1998

For: *AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITIONS,
METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE*

Art Unit: 1643

Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231, on this date.

10/22/98
Date


Kathy Holloway

**INFORMATION DISCLOSURE STATEMENT
IN ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

RECORDED
50 OCT 28 PM 3:02
GROUP 100

Dear Sir:

Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the Merits for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 08-1641.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (14 pages) are provided herewith. Copies of the references listed on the Form PTO-1449 are not provided herewith as they have been previously provided in connection with U.S. Serial No. 08/700,565, which claims priority of Provisional U.S. Application Serial No. 60/044,693 (converted from 08/506,668), and which is relied upon for an earlier filing date in accordance with 35 U.S.C. §120. The documents that are cited in connection

U.S.S.N. 09/127,138
GRUENBERG
INFORMATION DISCLOSURE STATEMENT

with this application are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant also makes known to the Examiner the following related, co-pending applications:

<u>U.S.S.N.</u>	<u>Inventor</u>	<u>Filing Date</u>
09/127,411	GRUENBERG	7/31/98
09/127,142	GRUENBERG	7/31/98
09/127,141	GRUENBERG	7/31/98

<u>PCT Application Serial No.</u>	<u>Inventor</u>	<u>Filing Date</u>
PCT/US96/12170	GRUENBERG	7/24/96

Applicant respectfully requests that the Examiner review the foregoing references and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE

By:


Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24731-500E
Address all correspondence to:
HELLER, EHRMAN, WHITE & McAULIFFE
4250 Executive Square, Suite 700,
La Jolla, California 92037
Telephone: (619) 450-8403
EMAIL sseidman@hewm.com